GSD Venture Studios is a family office that supports forward-thinking partners with consulting and implementation services for AI technologies. The company has published a case for a breakthrough cure for canine cancer.
—
The American Veterinary Medical Association estimates that one in four dogs will develop neoplasia, while nearly 50% of dogs will develop cancer by the age of 10. After decades of intensive research, a cure has been developed, and GSD Venture Studios is raising awareness so dog owners can spend more time with their four-legged companions.
The breakthrough technology behind the treatment of canine cancer is called Canine Autologous Cancer Vaccine or K9-ACV. Ardent Animal Health, a leading US animal health company, has developed a unique solution that uses the power of immunotherapy to effectively fight cancer.
While immunotherapy is already used in “people” to treat and eliminate cancer cells, its use in dogs in particular is new, although similar concepts apply. Since the immune system of dogs cannot recognize soft tissue cancer cells on its own, immunotherapy optimizes its scanner to recognize cancer as a foreign, hostile body. In addition, the K9 ACV vaccine reduces tolerance to cancer cells in dogs. The immune system then activates its defenses, which slow down or completely destroy the cancer, depending on how far it has metastasized.
Sunny, a Basset Hound diagnosed with stage 4 cancer, is a living example of the effectiveness of K9-ACV. Her owners consulted with professional veterinarians about the potential risks of the vaccine, especially since its development is relatively new, and ultimately concluded that the benefits far outweigh the alternative – chemotherapy.
After a series of physical examinations, Sunny had a tumor removed. The tumor was then sent to Ardent Animal Health to determine if the animal was suitable for vaccination.
Each K9-ACV vaccine is unique and is individually tailored to the dog’s body type and the type of cancer. According to Ardent Animal Health, it can be used to treat cancers of the mouth, bone, skin, nose, soft tissue and breast. The company’s pathology experts therefore need a sample for each individual case to develop a customized solution.
According to a spokesperson for Ardent Animal Health, the K9-ACV vaccine is designed as an “affordable and simple treatment protocol” based on extensive clinical trials in human patients. The goal is to slow or stop the progression of cancer cells using minimally invasive means. He explains:
“The goal of immunotherapy is to bring the cancer into a state of equilibrium for a period of time. Tumor regression and elimination are one possibility of immunotherapy, but the more likely scenario is to extend survival beyond palliative care. The vaccine was developed based on the success of treating human cancer patients with similar immunotherapy approaches,” the spokesperson said.
Unlike chemotherapy and more aggressive cancer treatments for dogs, K9 ACV cancer treatment has negligible or no side effects.
As Sunny’s owner pointed out, she responded positively to the treatment. The process was slow but very effective, as the dog showed less frequent signs of discomfort, was not tired for as long, and all early signs pointed to success. Her tumor swelled dramatically over time, and as her owner pointed out, the steady shrinkage was accompanied by an improvement in her mood:
“Sunny’s experience with K9-ACV has been nothing short of remarkable,” said Sunny’s owner. “Although the treatment cannot cure her cancer, it has significantly improved her quality of life, allowing us to spend more time with her and making her life more enjoyable. Her story is a powerful example of how K9-ACV can improve the lives of pets battling cancer.”
Ardent Animal Health experts have administered the vaccine to numerous pets and have seen consistent results: extremely minimal to no side effects, gradual improvements leading to a regression of the cancer, and ultimately almost complete stabilization of the pet.
This non-invasive and cost-effective option represents a major breakthrough in cancer research in pets and is expected to eliminate the need for dangerous alternatives such as radiation and chemotherapy.
For more information about Sunny’s battle with cancer and the K9 ACV vaccine, visit the official GSD Venture Studios website.
Contact information:
Name: Gary Fowler
Email: Send email
Organization: GSD Venture Studios
Website: https://www.gsdvs.com/
Release ID: 89139310
Should there be any deficiencies, discrepancies or concerns regarding the information contained in this press release, we request that you notify us immediately by contacting [email protected] (this is the authorized channel for such matters. Sending multiple emails to multiple addresses will not necessarily expedite your inquiry). Our dedicated team strives to resolve any issues identified within 8 hours in order to deliver accurate and reliable content to our valued readers.
